Compare DIT & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DIT | ANVS |
|---|---|---|
| Founded | 1981 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.1M | 69.1M |
| IPO Year | 1996 | 2019 |
| Metric | DIT | ANVS |
|---|---|---|
| Price | $72.90 | $1.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 510.0 | ★ 1.1M |
| Earning Date | 04-20-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,392,388,157.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.30 | N/A |
| 52 Week Low | $68.00 | $1.54 |
| 52 Week High | $126.50 | $5.50 |
| Indicator | DIT | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 37.18 | 40.63 |
| Support Level | N/A | $1.73 |
| Resistance Level | $120.08 | $2.34 |
| Average True Range (ATR) | 1.49 | 0.12 |
| MACD | -0.56 | -0.00 |
| Stochastic Oscillator | 31.96 | 8.22 |
Amcon Distributing Co is engaged in the wholesale and retail distribution of consumer products such as cigarettes, tobacco, confectionery, health food, and others. It operates in two segments: Wholesale distribution segment distributing consumer products to the retail outlets including convenience stores, grocery stores, liquor stores, drug stores and tobacco shops in the Central, Rocky Mountain, and Southern regions of the United States; and the Retail health food segment is a specialty retailer of natural/organic groceries and dietary supplements throughout the Midwest and Florida. The company earns a majority of the revenue from the Wholesale distribution segment.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.